Last10K.com

Acasti Pharma Inc. (ACST) SEC Filing 10-Q Quarterly Report for the period ending Friday, December 31, 2021

SEC Filings

Acasti Pharma Inc.

CIK: 1444192 Ticker: ACST
Document And Entity Information - shares
9 Months Ended
Dec. 31, 2021
Feb. 14, 2022
Cover [Abstract]  
Entity Central Index Key0001444192 
Entity Registrant NameAcasti Pharma Inc. 
Amendment Flagfalse 
Current Fiscal Year End Date--03-31 
Document Fiscal Period FocusQ3 
Document Fiscal Year Focus2021 
Document Type10-Q 
Document Quarterly Reporttrue 
Document Period End DateDec. 31, 2021 
Document Transition Reportfalse 
Entity File Number001-35776 
Entity Incorporation, State or Country CodeZ4 
Entity Tax Identification Number98-1359336 
Entity Address, Address Line One3009 boul. de la Concorde East, Suite 102 
Entity Address, City or TownLaval 
Entity Address, State or ProvinceQC 
Entity Address, CountryCA 
Entity Address, Postal Zip CodeH7E 2B5 
City Area Code450 
Local Phone Number686-4555 
Title of 12(b) SecurityCommon Shares, no par value per share 
Trading SymbolACST 
Security Exchange NameNASDAQ 
Entity Current Reporting StatusYes 
Entity Interactive Data CurrentYes 
Entity Filer CategoryNon-accelerated Filer 
Entity Small Businesstrue 
Entity Emerging Growth Companyfalse 
Entity Shell Companyfalse 
Entity Common Stock, Shares Outstanding 44,288,183

View differences made from one quarter to another to evaluate Acasti Pharma Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Acasti Pharma Inc..

Continue

Assess how Acasti Pharma Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Acasti Pharma Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Legal
M & A
Other
Filter Subcategory:
All
Shares
Expense
Product
Geography
Cash Flow
Other
Inside Acasti Pharma Inc.'s 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Interim Balance Sheet (Current Period Unaudited)
Condensed Consolidated Interim Statements Of Cash Flows (Unaudited)
Condensed Consolidated Interim Statements Of Changes In Shareholder's Equity (Unaudited)
Condensed Consolidated Interim Statements Of Loss And Comprehensive Loss (Unaudited)
Note 1 - Nature Of Operation
Note 1 - Nature Of Operation (Details Textual)
Note 10 - Government Assistance
Note 10 - Government Assistance (Details Textual)
Note 11 - Revenues
Note 12 - Net Financial Income
Note 12 - Net Financial Income (Tables)
Note 12 - Net Financial Income - Financial Income (Expenses) (Details)
Note 13 - Stock Based Compensation
Note 13 - Stock Based Compensation (Details Textual)
Note 13 - Stock Based Compensation (Tables)
Note 13 - Stock Based Compensation - Activities Within The Stock Option Plan (Details)
Note 13 - Stock Based Compensation - Compensation Expense (Details)
Note 13 - Stock-Based Compensation - Schedule Of Fair Value Of Options Granted (Details)
Note 14 - Supplemental Cash Flow Disclosure
Note 14 - Supplemental Cash Flow Disclosure (Tables)
Note 14 - Supplemental Cash Flow Disclosure - Changes In Working Capital Items (Details)
Note 15 - Commitments And Contingencies
Note 15 - Commitments And Contingencies (Details Textual)
Note 2 - Summary Of Significant Accounting Policies
Note 3 - Recent Accounting Pronouncements
Note 4 - Acquisition Of Grace
Note 4 - Acquisition Of Grace (Details Textual)
Note 4 - Acquisition Of Grace (Tables)
Note 4 - Acquisition Of Grace - Assets Acquired And Liabilities Assumed (Details)
Note 4 - Acquisition Of Grace - Consideration (Details)
Note 4 - Acquisition Of Grace - Pro Forma Financial Information (Details)
Note 5 - Short-Term Investments
Note 5 - Short-Term Investments (Tables)
Note 5 - Short-Term Investments - Marketable Securities (Details)
Note 6 - Impairment Of Intangible Assets
Note 6 - Impairment Of Intangible Assets (Details Textual)
Note 7 - Assets Held For Sale
Note 7 - Assets Held For Sale (Additional Information) (Details)
Note 7 - Assets Held For Sale (Tables)
Note 7 - Assets Held For Sale - Summary Of Assets Held For Sale (Details)
Note 8 - Derivative Warrant Liabilities
Note 8 - Derivative Warrant Liabilities (Details Textual)
Note 8 - Derivative Warrant Liabilities (Tables)
Note 8 - Derivative Warrant Liabilities - Assumptions (Details)
Note 8 - Derivative Warrant Liabilities - Changes In Fair Value (Details)
Note 9 - Capital And Other Components Of Equity
Note 9 - Capital And Other Components Of Equity (Details Textual)
Note 9 - Capital And Other Components Of Equity (Tables)
Note 9 - Capital And Other Components Of Equity - Warrants (Details)
Significant Accounting Policies (Policies)

Material Contracts, Statements, Certifications & more

Acasti Pharma Inc. provided additional information to their SEC Filing as exhibits

Ticker: ACST
CIK: 1444192
Form Type: 10-Q Quarterly Report
Accession Number: 0000950170-22-001147
Submitted to the SEC: Mon Feb 14 2022 6:30:40 AM EST
Accepted by the SEC: Mon Feb 14 2022
Period: Friday, December 31, 2021
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/acst/0000950170-22-001147.htm